LinkedIn
Twitter
Facebook
YouTube
Take Action
About
Advocacy
Events
Resources
2024 Savings Report
FDA-Approved Biosimilars
Interchangeability
Reports & White Papers
Research & Studies
Streamlining
Biosimilars Timeline
Blog
Press Releases
Blog
Home
/
Blog
February 3, 2025
Blog
The Biosimilar Void: A Crisis in Patient Access and a Call to Action
November 8, 2024
Blog
GRx+Biosims Market Leaders Lessons for Biosimilars
October 3, 2024
Blog
Don’t Fall for PhRMA’s Misinformation – Biosimilars Are Safe, Effective, and So is the Biosimilar Red Tape Elimination Act
September 25, 2024
Blog
FTC’s Pattern of Abuses Will Lead to Higher Drug Prices for America’s Patients
July 26, 2024
Blog
Misinformation on Biosimilars Costs Billions, Harms Patients, and Sows Unnecessary Doubt Around FDA-Approved Products
April 24, 2024
Blog
Readout from the 2024 Festival of Biologics
March 19, 2024
Blog
PBMs Continue to Block Patient Access to Lower-Priced Biosimilar Insulin
January 30, 2024
Blog
Humira Biosimilar Landscape: Still Waiting
December 11, 2023
Blog
What Are Interchangeable Biologics?
November 16, 2023
Blog
Provider Shared Savings is Key to Driving Greater Adoption of Biosimilars
July 17, 2023
Blog
Pharmacy Benefit Managers Are Blocking Patient Access to Biosimilar Insulin
June 8, 2023
Blog
IQVIA Highlights Progress and Warning Signs for Biosimilar Savings
May 16, 2023
Blog
When is a Smaller Discount Better? How Upside-Down Pharmaceutical Incentives Lock Patients Into High Costs
March 3, 2023
Blog
Event
Blog – Access! 2023 – Takeaways for the Biosimilars Industry
February 21, 2023
Blog
Humira Biosimilars: Ending a Monopoly, but Savings Will Take Time
November 23, 2022
Blog
Event
GRx+Biosims 2022 Conference Recap
October 25, 2022
Blog
Savings Report Shows the Value of Biosimilars for Patients with Cancer
October 12, 2022
Blog
Pharmacists Can Help Spur Greater Biosimilar Adoption
October 6, 2022
Blog
Biosimilars Reach More Patients in 2022, Yet Challenges Remain
August 15, 2022
Blog
Health Care Professionals’ Perspectives are Essential to Greater Biosimilar Adoption
July 26, 2022
Blog
Drug Price Negotiation Proposals Undermine Current Bipartisan Approaches to Lower Drug Spending
May 23, 2022
Blog
AAM Calls for Federal Trade Commission to Investigate PBM Business Practices
May 20, 2022
Blog
Everything You Need to Know About Biosimilars – All in One Place
April 8, 2022
Blog
HHS OIG Report Demonstrates Need for Changes to Part D to Increase Biosimilar Use
March 23, 2022
Blog
Treating Ulcerative Colitis, and Enjoying a Slice or Two
March 15, 2022
Blog
Singing, Dancing and Taking Care of Herself with Biosimilars
March 11, 2022
Blog
BsUFA Reauthorization and Modernization Is the Key to a Healthy Biosimilar Market
February 24, 2022
Blog
Event
Access! 2022 Conference Recap
February 4, 2022
Blog
Increase Patient Access to Biosimilars in 2022
February 2, 2022
Blog
Biosimilar Medicines Bring New Optimism on RA Awareness Day
December 20, 2021
Blog
Proposed BBB Negotiation Framework Discourages Biosimilar Competition, Imposes Higher Costs on Commercially Insured Patients and Their Employers
December 3, 2021
Blog
The Evidence Is Clear: Biosimilar Competition Will Achieve More Savings for Patients Than Build Back Better’s Negotiations
October 28, 2021
Blog
Patients Increasingly Rely on Oncology Biosimilar Medicines
October 14, 2021
Blog
AAM Annual Savings Report – Biosimilars and Bending the Cost Curve
July 27, 2021
Blog
Increase Patient Access to Lower-Cost Biosimilar Medicines
July 1, 2021
Blog
Organizations Thank Rep. Schrader, Kinzinger for Introducing the BIOSIM Act
June 28, 2021
Blog
Increasing Provider Reimbursement for Biosimilars Will Lead to Greater Adoption
June 11, 2021
Blog
Biosimilar Medicines Equal More Accessible Care for America’s Patients
May 7, 2021
Blog
IQVIA Report Highlights Options to Boost U.S. Provider Use of Biosimilars
April 20, 2021
Blog
Access! 2021 Is Coming. Here’s What You Need to Know
March 25, 2021
Blog
New Analyses Point to Opportunities to Increase Savings from Biosimilar Adoption
February 4, 2021
Blog
Cancer Costs and Options for Care in the United States
December 22, 2020
Blog
Biosimilars Facts
November 16, 2020
Blog
Biosimilars Council Joins IGBA in Celebrating Global Biosimilars Week
November 10, 2020
Blog
Affordable Care Act and the Future of Biosimilars
October 26, 2020
Blog
Ten Years of Biosimilars in the U.S.
October 12, 2020
Blog
Patent Abuse Blocks Patient Access to Needed Biosimilars
October 5, 2020
Blog
How a Biosimilar is Developed
September 28, 2020
Blog
Advocacy for Patient Access to Biosimilars
September 21, 2020
Blog
What are biosimilars?
April 6, 2020
Blog
ERIC Launches Initiative to Understand Biosimilars Potential to Lower Health Care Costs
March 4, 2020
Blog
Biosimilars Study Shows Massive State Savings Potential
January 30, 2020
Blog
Biosimilars Council 2019 Year in Review
November 21, 2019
Blog
Event
GRx+Biosims 2019 Conference: Advancing Biosimilars Access
October 2, 2019
Blog
FDA Releases New Biosimilars Education Materials for Patients
June 24, 2019
Blog
Biosimilar Benefits to Patients, Health Care Professionals and the U.S. Market
July 29, 2019
Blog
The Importance of Naming for Market Adoption of Biosimilars
May 9, 2019
Blog
Chip Davis: “The Biosimilars Wave is Coming. Are Pharmacists Prepared?”
May 9, 2019
Blog
Abandoning Biosimilars Leaves Savings on the Table and Patients in the Lurch
April 22, 2019
Blog
Bipartisan Legislation Targets Patent Thickets, Supports Biosimilars Uptake
February 22, 2019
Blog
Biosimilars Council Recap of Access! 2019
February 4, 2019
Blog
Brand Efforts Seek to Limit Patient Access to Biosimilars
December 10, 2018
Blog
FDA Approval of Biosimilars Picking Up Pace
November 18, 2018
Blog
New Resource: Biosimilars Education Course for Clinicians
November 15, 2018
Blog
Taking Steps to Increase Patient Access to Life Altering Biosimilar Medicines
November 14, 2018
Blog
Cleveland Clinic Chief Pharmacy Officer: Time to Pass the CREATES Act
November 13, 2018
Blog
New Study: Pharmacist Involvement Key to Reducing Cost of Biologics
October 16, 2018
Blog
Pharmacists: On the Front Lines of Biosimilar Education
September 25, 2018
Blog
IQVIA Releases Report Detailing Sustainability of Biosimilars in European Markets
September 11, 2018
Blog
AAM This Month – August
September 2, 2018
Blog
Health Organizations Pen Letter to FDA Encouraging Action on Interchangeability Guidance
August 31, 2018
Blog
Biosimilars Council Joins Other North American Generic Drugmakers in Rejection of New Exclusivity Period for Biologics
August 20, 2018
Blog
New Council Partnerships Boost Patient Understanding of Biosimilars’ Benefits
May 4, 2018
Blog
The Biosimilars Council Congressional Briefing: Five Takeaways
April 13, 2018
Blog
Misinformation on Biosimilars Undermines Patient and Prescriber Confidence
March 15, 2018
Blog
The Naming of Biosimilar Medicines Worldwide Should Promote Patient Safety and Prescriber Confidence
March 1, 2018
Blog
Why Increasing Patient Awareness of Biosimilars Is Important
February 15, 2018
Blog
FDA’s Steps to Improve Biosimilars Access in 2017 and Beyond
February 7, 2018
Blog
Why Biosimilars Are Important for Patients
December 19, 2017
Blog
A Watershed Year for Biosimilars in the U.S.
December 1, 2017
Blog
Mind the Gap: Realizing Savings and Increasing Patient Access to Biosimilars in Medicare Part D
October 4, 2017
Blog
Forging a Path: How We Are Leading on Access to Biosimilars
September 1, 2017
Blog
Event
Leading on Biosimilars: 2017 AAM Biosimilars Council Conference Preview
July 25, 2017
Blog
New Study: Biosimilars Earn the Trust of Health Insurers
June 27, 2017
Blog
Event Recap: The Next Drugs: The Future for Biosimilars
June 6, 2017
Blog
Biosimilars Council & The Atlantic: The Next Drugs: The Future for Biosimilars
May 25, 2017
Blog
The Next Drugs: An Atlantic Policy Update on Biosimilars
May 8, 2017
Blog
Supreme Court Hears Biosimilars Patent Case
March 28, 2017
Blog
Recapping: The Future For Biosimilars (an Atlantic policy briefing)
Load more
MENU
About
Advocacy
Events
Resources
2024 Savings Report
FDA-Approved Biosimilars
Interchangeability
Reports & White Papers
Research & Studies
Streamlining
Biosimilars Timeline
Blog
Press Releases
